{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.0","upperLimit":"2.5","value":"0.8"},{"groupId":"OG001","lowerLimit":"0.0","upperLimit":"4.3","value":"1.8"},{"groupId":"OG002","lowerLimit":"0.0","upperLimit":"5.7","value":"2.7"},{"groupId":"OG003","lowerLimit":"2.8","upperLimit":"8.6","value":"5.7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"121"},{"groupId":"OG001","value":"125"},{"groupId":"OG002","value":"113"},{"groupId":"OG003","value":"248"}],"units":"Participants"}],"description":"To assess whether intensification of CNS-directed intrathecal and systemic chemotherapy will improve outcome in patients at high-risk of CNS relapse.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients randomized on the first day of continuation phase to receive 3500 units/m\\^2 dose of PEG-asparaginase","id":"OG000","title":"TOTXVI PEG 3500"},{"description":"Patients randomized on the first day of continuation phase to receive 2,500 units/m\\^2 dose of PEG-asparaginase","id":"OG001","title":"TOTXVI PEG 2500"},{"description":"Patients who came off study prior to randomization","id":"OG002","title":"TOTXVI Not Randomized"},{"description":"Patients with features associated with increased risk for CNS relapse in Total XV","id":"OG003","title":"All Eligible Patients in TOTXV"}],"paramType":"NUMBER","populationDescription":"Patients with features associated with increased risk for CNS relapse in Total XVI and Total XV.","reportingStatus":"POSTED","timeFrame":"For Total XVI: 3.5 years after the last enrollment, up to approximately 13.5 years For Total XV: patients are followed continuously, up to 20.5 years","title":"Probability of CNS Relapse","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}